Published in PPAR Res on December 12, 2011
Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res (2012) 1.14
Diabetes and thyroid cancer risk: literature review. Exp Diabetes Res (2012) 1.02
Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. J Clin Endocrinol Metab (2013) 0.88
Nuclear factor κB-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8. J Clin Endocrinol Metab (2014) 0.88
Pax-8-PPAR-γ fusion protein in thyroid carcinoma. Nat Rev Endocrinol (2014) 0.85
The thyroid cancer PAX8-PPARG fusion protein activates Wnt/TCF-responsive cells that have a transformed phenotype. Endocr Relat Cancer (2013) 0.81
Characterization of thyroid cancer cell lines in murine orthotopic and intracardiac metastasis models. Horm Cancer (2015) 0.80
Anti- and Protumorigenic Effects of PPARγ in Lung Cancer Progression: A Double-Edged Sword. PPAR Res (2012) 0.77
FAK Expression, Not Kinase Activity, Is a Key Mediator of Thyroid Tumorigenesis and Protumorigenic Processes. Mol Cancer Res (2016) 0.75
PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis. Front Endocrinol (Lausanne) (2017) 0.75
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab (2008) 5.94
The PPARs: from orphan receptors to drug discovery. J Med Chem (2000) 5.29
Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med (1998) 5.16
Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A (1997) 3.22
Cyclin A in cell cycle control and cancer. Cell Mol Life Sci (2002) 2.49
Role of PPARgamma in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis. J Biol Chem (1999) 1.96
PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol (2002) 1.70
Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab (2001) 1.65
PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev (2004) 1.58
Peroxisome proliferator-activated receptor-gamma activation inhibits tumor progression in non-small-cell lung cancer. Oncogene (2004) 1.50
Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene (2006) 1.45
Peroxisome proliferator-activated receptor-gamma (PPAR(gamma)) inhibits tumorigenesis by reversing the undifferentiated phenotype of metastatic non-small-cell lung cancer cells (NSCLC). Oncogene (2005) 1.40
PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast Cancer Res Treat (2003) 1.39
PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway. Oncogene (2006) 1.28
Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology (2006) 1.23
Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more.... Chem Biol (1995) 1.19
Intestinal-specific PPARgamma deficiency enhances tumorigenesis in ApcMin/+ mice. Int J Cancer (2006) 1.18
Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth. Cancer Res (2009) 1.16
Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab (2002) 1.12
Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions: immunocytochemical and quantitative image analyses. Am J Pathol (1997) 1.12
Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. Hepatology (2010) 1.05
PPARgamma controls cell proliferation and apoptosis in an RB-dependent manner. Oncogene (2003) 1.05
PPARgamma-independent antitumor effects of thiazolidinediones. Cancer Lett (2008) 1.03
A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer. Surgery (2006) 1.02
The roles of PPARs in adipocyte differentiation. Prog Lipid Res (2001) 1.01
The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion. Mol Cancer Ther (2007) 0.99
Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid (2005) 0.99
Ligands for peroxisome proliferator-activated receptor gamma inhibit growth of pancreatic cancers both in vitro and in vivo. Int J Cancer (2001) 0.96
In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma. Clin Cancer Res (2008) 0.94
Peroxisome proliferator-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells. Jpn J Cancer Res (2002) 0.93
Troglitazone suppresses cell growth of KU812 cells independently of PPARgamma. Eur J Pharmacol (2002) 0.93
Inhibition of cell motility by troglitazone in human ovarian carcinoma cell line. BMC Cancer (2007) 0.91
PPARgamma and colorectal carcinoma: conflicts in a nuclear family. Nat Med (1998) 0.90
Management of undifferentiated thyroid cancer. Baillieres Best Pract Res Clin Endocrinol Metab (2000) 0.89
Peroxisome proliferator-activated receptor gamma is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas. Oncogene (2003) 0.89
Peroxisome proliferator-activated receptor gamma inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner. Endocr Relat Cancer (2008) 0.87
Antitumor effects of peroxisome proliferator activate receptor gamma ligands on anaplastic thyroid carcinoma. Int J Oncol (2004) 0.86
Evaluation of peroxisome proliferator-activated receptor-gamma expression in benign and malignant thyroid pathologies. Thyroid (2005) 0.83
Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression. Mol Cancer (2009) 0.83
Effect of peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, on dedifferentiated thyroid cancers. Nucl Med Commun (2004) 0.81
The Putative PAX8/PPARγ Fusion Oncoprotein Exhibits Partial Tumor Suppressor Activity through Up-Regulation of Micro-RNA-122 and Dominant-Negative PPARγ Activity. Genes Cancer (2011) 0.81
Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2009) 35.34
Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid (2006) 12.23
Mobile elements create structural variation: analysis of a complete human genome. Genome Res (2009) 7.06
Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med (2012) 7.06
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab (2008) 5.94
Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab (2009) 3.23
Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid (2006) 3.03
Looking forward, looking back: assessing variations in hospital resource use and outcomes for elderly patients with heart failure. Circ Cardiovasc Qual Outcomes (2009) 2.80
Prevalence of coronary heart disease and risk factors in an urban Indian population: Jaipur Heart Watch-2. Indian Heart J (2002) 2.79
The efficacy of zoledronic acid in breast cancer adjuvant therapy: a meta-analysis of randomised controlled trials. Eur J Cancer (2011) 2.55
Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell (2009) 2.50
Progress in molecular-based management of differentiated thyroid cancer. Lancet (2013) 2.44
Cross-platform comparison of SYBR Green real-time PCR with TaqMan PCR, microarrays and other gene expression measurement technologies evaluated in the MicroArray Quality Control (MAQC) study. BMC Genomics (2008) 1.99
Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med (2006) 1.86
Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. Thyroid (2009) 1.73
Tumor-specific changes in mtDNA content in human cancer. Int J Cancer (2005) 1.70
Very high fructose intake increases serum LDL-cholesterol and total cholesterol: a meta-analysis of controlled feeding trials. J Nutr (2013) 1.65
Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab (2009) 1.59
Interplay of Th1 and Th17 cells in murine models of malignant pleural effusion. Am J Respir Crit Care Med (2014) 1.57
Prevalence, outcome and pre-hospital management of anaphylaxis by first aiders and paramedical ambulance staff in Manchester, UK. Resuscitation (2010) 1.53
Expanding indications for recombinant human TSH in thyroid cancer. Thyroid (2008) 1.49
Apigenin inhibits expression of vascular endothelial growth factor and angiogenesis in human lung cancer cells: implication of chemoprevention of lung cancer. Mol Pharmacol (2005) 1.47
A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab (2006) 1.45
Uses for recombinant human TSH in patients with thyroid cancer and nodular goiter. Clin Endocrinol (Oxf) (2004) 1.43
Recurrence after treatment of micropapillary thyroid cancer. Thyroid (2009) 1.41
Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and P70S6K1 in human ovarian cancer cells. Free Radic Biol Med (2006) 1.32
TNFR2 is critical for the stabilization of the CD4+Foxp3+ regulatory T. cell phenotype in the inflammatory environment. J Immunol (2012) 1.26
Generation and differentiation of IL-17-producing CD4+ T cells in malignant pleural effusion. J Immunol (2010) 1.26
Apigenin inhibits tumor angiogenesis through decreasing HIF-1alpha and VEGF expression. Carcinogenesis (2006) 1.25
3D models of epithelial-mesenchymal transition in breast cancer metastasis: high-throughput screening assay development, validation, and pilot screen. J Biomol Screen (2011) 1.24
Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab (2004) 1.22
Programmed death-1+ T cells and regulatory T cells are enriched in tumor-involved lymph nodes and associated with aggressive features in papillary thyroid cancer. J Clin Endocrinol Metab (2012) 1.21
A prospective assessment defining the limitations of thyroid nodule pathologic evaluation. Ann Intern Med (2013) 1.19
Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol Carcinog (2006) 1.17
Estimates of smoking-related property costs in California multiunit housing. Am J Public Health (2011) 1.16
Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells. Carcinogenesis (2006) 1.14
Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis. Clin Cancer Res (2012) 1.14
Multicenter clinical experience with the Afirma gene expression classifier. J Clin Endocrinol Metab (2013) 1.13
Tumor-associated lymphocytes and increased FoxP3+ regulatory T cell frequency correlate with more aggressive papillary thyroid cancer. J Clin Endocrinol Metab (2010) 1.13
Variations in disaster preparedness by mental health, perceived general health, and disability status. Disaster Med Public Health Prep (2009) 1.13
Prognosis of differentiated thyroid cancer in relation to serum thyrotropin and thyroglobulin antibody status at time of diagnosis. Thyroid (2013) 1.12
Terrorism-related fear and avoidance behavior in a multiethnic urban population. Am J Public Health (2008) 1.11
Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J Clin Endocrinol Metab (2009) 1.11
Monitoring post-translational modification of proteins with allosteric ribozymes. Nat Biotechnol (2002) 1.11
Differentiation and recruitment of Th9 cells stimulated by pleural mesothelial cells in human Mycobacterium tuberculosis infection. PLoS One (2012) 1.08
Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Mol Cancer Ther (2004) 1.08
Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid (2013) 1.07
The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer. Am J Clin Pathol (2004) 1.05
Radioiodine therapy in patients with stage I differentiated thyroid cancer. Thyroid (2010) 1.04
The Saccharomyces cerevisiae high mobility group box protein HMO1 contains two functional DNA binding domains. J Biol Chem (2004) 0.98
Caspase-3 status is a determinant of the differential responses to genistein between MDA-MB-231 and MCF-7 breast cancer cells. Biochim Biophys Acta (2007) 0.97
Imbalance of Th17 cells and regulatory T cells in tuberculous pleural effusion. Clin Vaccine Immunol (2011) 0.96
Quantitative analysis of telomerase hTERT mRNA and telomerase activity in endometrioid adenocarcinoma and in normal endometrium. Gynecol Oncol (2002) 0.96
Discovery and validation of protein abundance differences between follicular thyroid neoplasms. Cancer Res (2008) 0.96
In vivo and microarray analysis of rexinoid-responsive anaplastic thyroid carcinoma. Clin Cancer Res (2008) 0.94
Effects of hydroquinone and its glucoside derivatives on melanogenesis and antioxidation: Biosafety as skin whitening agents. J Dermatol Sci (2009) 0.94
Improving Latino disaster preparedness using social networks. Am J Prev Med (2009) 0.93
Retinoid X receptor gamma-deficient mice have increased skeletal muscle lipoprotein lipase activity and less weight gain when fed a high-fat diet. Endocrinology (2004) 0.93
CCL22 is involved in the recruitment of CD4+CD25 high T cells into tuberculous pleural effusions. Respirology (2010) 0.92
Interleukin 22-producing CD4+ T cells in malignant pleural effusion. Cancer Lett (2012) 0.91
Differentiation and immune regulation of IL-9-producing CD4+ T cells in malignant pleural effusion. Am J Respir Crit Care Med (2012) 0.90
Differentiation and recruitment of IL-22-producing helper T cells stimulated by pleural mesothelial cells in tuberculous pleurisy. Am J Respir Crit Care Med (2011) 0.90
Inhibition of excitatory amino acid efflux contributes to protective effects of puerarin against cerebral ischemia in rats. Biomed Environ Sci (2007) 0.90
Effects of rexinoids on thyrotrope function and the hypothalamic-pituitary-thyroid axis. Endocrinology (2005) 0.89
Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PLoS One (2012) 0.89
Tissue microarrays in Chinese human rectal cancer: study of expressions of the tumor-associated genes. Hepatogastroenterology (2012) 0.88
Regulation of DHICA-mediated antioxidation by dopachrome tautomerase: implication for skin photoprotection against UVA radiation. Free Radic Biol Med (2010) 0.88
Synthesis and characterization of monosaccharide lipids as novel hydrogelators. Carbohydr Res (2006) 0.88
Nuclear factor κB-dependent regulation of angiogenesis, and metastasis in an in vivo model of thyroid cancer is associated with secreted interleukin-8. J Clin Endocrinol Metab (2014) 0.88
Inhibition of nuclear factor-kappa B differentially affects thyroid cancer cell growth, apoptosis, and invasion. Mol Cancer (2010) 0.87
Cell origins and diagnostic accuracy of interleukin 27 in pleural effusions. PLoS One (2012) 0.87
Serum albumin is a useful prognostic indicator and adds important information to NT-proBNP in a Chinese cohort of heart failure. Clin Biochem (2012) 0.86
SPECT/CT of metastatic struma ovarii. Clin Nucl Med (2014) 0.86
[Correlation between FoxP3(+) regulatory T cells and chronic obstructive pulmonary disease]. Zhonghua Yi Xue Za Zhi (2008) 0.86
First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysis. PLoS One (2012) 0.85
Neoamphimedine circumvents metnase-enhanced DNA topoisomerase IIα activity through ATP-competitive inhibition. Mar Drugs (2011) 0.85
Salidroside protects PC12 cells from MPP⁺-induced apoptosis via activation of the PI3K/Akt pathway. Food Chem Toxicol (2012) 0.84
Sensitivity to cigarette prices among individuals with alcohol, drug, or mental disorders. Am J Public Health (2010) 0.84
An immunohistochemical method that distinguishes free from complexed SNAP-25. J Neurosci Res (2004) 0.84
IL-27 and IL-27-producing CD4+ T cells in human tuberculous pleural effusion. Tuberculosis (Edinb) (2014) 0.84
The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures. Breast Cancer Res Treat (2011) 0.84
Bio-inspired superhydrophobic polyphenylene sulfide/polytetrafluoroethylene coatings with high performance. J Nanosci Nanotechnol (2012) 0.84
Mineral trioxide aggregate versus calcium hydroxide for pulpotomy in primary molars. Chin J Dent Res (2011) 0.84
Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer. Mol Cancer (2014) 0.84
Correlation of survivin mRNA detection with histologic diagnosis in normal endometrium and endometrial carcinoma. Acta Obstet Gynecol Scand (2002) 0.83
Retinoid and thiazolidinedione therapies in melanoma: an analysis of differential response based on nuclear hormone receptor expression. Mol Cancer (2009) 0.83